Research Articles | Page 100 | Aplastic Anemia & MDS International Foundation Return to top.

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function Apr 2014 Ann Hematol myelodysplastic syndromes (MDS)
Biomarkers for predicting clinical response to immunosuppressive therapy in aplastic anemia Apr 2016 Int J Hematol aplastic anemia
Bilateral central serous retinopathy in a patient with paroxysmal nocturnal hemoglobinuria treated with deferoxamine Jul 2016 Eur J Ophthalmol paroxysmal nocturnal hemoglobinuria (PNH)
Beyond hypomethylating agents failure in patients with myelodysplastic syndromes Dec 2013 Curr Opin Hematol myelodysplastic syndromes (MDS)
Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International PNH Registry Jul 2020 European Journal of Haematology paroxysmal nocturnal hemoglobinuria (PNH)
BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Sep 2013 Blood myelodysplastic syndromes (MDS)
Baseline Clinical Characteristics and Disease Burden in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Updated Analysis From the International PNH Registry Jul 2020 Annals of Hematology paroxysmal nocturnal hemoglobinuria (PNH)
Baseline Clinical Characteristics and Disease Burden in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Updated Analysis From the International PNH Registry May 2020 Annals of Hematology paroxysmal nocturnal hemoglobinuria (PNH)
Baseline characteristics and disease burden in patients in the international paroxysmal nocturnal hemoglobinuria registry Jan 2014 Haematologica paroxysmal nocturnal hemoglobinuria (PNH)
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes Feb 2021 Blood Advances myelodysplastic syndromes (MDS)
Share with addtoany.com.